Charles River Laboratories International (NYSE:CRL) Sets New 12-Month Low - Time to Sell?

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s stock price reached a new 52-week low on Monday . The company traded as low as $147.69 and last traded at $148.88, with a volume of 99591 shares trading hands. The stock had previously closed at $155.55.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Finally, Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of "Hold" and an average price target of $189.77.

Remove Ads

Charles River Laboratories International Trading Down 2.6 %

The stock's fifty day simple moving average is $163.05 and its 200 day simple moving average is $181.41. The firm has a market capitalization of $7.02 billion, a PE ratio of 914.07, a PEG ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. During the same period last year, the firm earned $2.46 EPS. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth $601,000. JPMorgan Chase & Co. increased its stake in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. State Street Corp increased its stake in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $966,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).